2016 December
Volume : 4 Issue : 4

Management of hyperglycemia in diabetics with cardiovascular disease

Prasun Deb, Jaideep Khare, Ashish Kumar Jangir, RN Mehrotra

Pdf Page Numbers :- 196-201

 1Department of Endocrinology, Krishna Institute of Medical Sciences, Secunderabad, India.

2Department of Endocrinology, Apollo Hospital, Secunderabad, India


*Corresponding author: Dr. Prasun Deb, Head of Department of Endocrinology,

Krishna Institute of Medical Sciences, Hyderabad, India. Mobile No.: 09849054877; Email :


Received 04 August 2016; Revised 06 September 2016; Accepted 15 September 2016; Published 29 September 2016


Citation: Prasun D, Jaideep K, Ashish KJ, Mehrotra RN. Management of hyperglycemia in diabetics with cardiovascular disease. J Med Sci Res. 2016; 4(4):196-201. DOI:


Copyright: © 2016 Prasun D, et al. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

View Full Text | PDF


Diabetes mellitus is a syndrome characterized by hyperglycemia and dyslipidemia; and is associated with various systemic complications including acute metabolic emergencies and chronic complications, which includes microvascular and macrovascular manifestations. Coronary artery diseases are the major causes of morbidity and mortality. Various studies have convincingly demonstrated that managing hyperglycemia adequately is important for controlling diabetic complications, but macrovascular complications have not shown as significant reduction as have microvascular diseases. The cardiac safety of various anti-diabetic agents available to us also vary, which suggests that both euglycemia per se, as well the agent used to achieve it, are important considerations for cardiovascular safety. The Food and Drugs Administration of the United States of America has now stipulated that all anti-diabetic medications must undergo cardio-vascular outcome trials to prove cardiac safety before they are approved for use. Most currently available anti-diabetics are neutral on the heart, and may be continued safely in patients with chronic stable coronary artery disease (CAD). However, recent data from cardio-vascular outcome trials involving SGLT2-inhibitors and GLP1R-analogs demonstrate impressive cardiac safety data. Insulin still remains the agent of choice during recent acute coronary events and critical-care management.


Keywords: diabetes mellitus; hyperglycemia; macrovascular complication; coronary artery diseases; cardio-vascular outcome trials